A citation-based method for searching scientific literature

Stephen T Ryan, Vi Nguyen, Kelly K Bree, Daniel D Holst, A Karim Kader. Curr Opin Urol 2019
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature.
Shahrokh F Shariat, Pierre I Karakiewicz, Nazareno Suardi, Michael W Kattan. Clin Cancer Res 2008
208
100

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.
M W Kattan, J A Eastham, A M Stapleton, T M Wheeler, P T Scardino. J Natl Cancer Inst 1998
962
100



Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenaëlle Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen,[...]. Lancet 2010
100

A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer.
Claire Murphy, Lawrence True, Funda Vakar-Lopez, Jing Xia, Roman Gulati, Bruce Montgomery, Maria Tretiakova. Prostate 2016
6
100

A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
Paul R Womble, Peter J VanVeldhuizen, Alan A Nisbet, Greg A Reed, J Brantley Thrasher, Jeffrey M Holzbeierlein. J Urol 2011
24
100


Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy.
L H Klotz, S L Goldenberg, M A Jewett, Y Fradet, R Nam, J Barkin, J Chin, S Chatterjee. J Urol 2003
142
100

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Daniel P Petrylak, Catherine M Tangen, Maha H A Hussain, Primo N Lara, Jeffrey A Jones, Mary Ellen Taplin, Patrick A Burch, Donna Berry, Carol Moinpour, Manish Kohli,[...]. N Engl J Med 2004
100


Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
Rana R McKay, Huihui Ye, Wanling Xie, Rosina Lis, Carla Calagua, Zhenwei Zhang, Quoc-Dien Trinh, Steven L Chang, Lauren C Harshman, Ashley E Ross,[...]. J Clin Oncol 2019
48
100

Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer.
Neelima Denduluri, Kathy Miller, Ruth M O'Regan. Am Soc Clin Oncol Educ Book 2018
4
100

Time trends and local variation in primary treatment of localized prostate cancer.
Matthew R Cooperberg, Jeanette M Broering, Peter R Carroll. J Clin Oncol 2010
738
100

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Yohann Loriot, Kurt Miller, Cora N Sternberg, Karim Fizazi, Johann S De Bono, Simon Chowdhury, Celestia S Higano, Sarah Noonberg, Stefan Holmstrom, Harry Mansbach,[...]. Lancet Oncol 2015
139
100

First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
Laleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley, Amna Ibrahim, Robert Justice, Richard Pazdur, Patricia Cortazar. Clin Cancer Res 2014
104
100

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Mark Garzotto, Celestia S Higano, Catherine O'Brien, Brooks L S Rademacher, Nicole Janeba, Ladan Fazli, Paul H Lange, Stephen Lieberman, Tomasz M Beer. Cancer 2010
33
100

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Matthew R Cooperberg, Jeffry P Simko, Janet E Cowan, Julia E Reid, Azita Djalilvand, Satish Bhatnagar, Alexander Gutin, Jerry S Lanchbury, Gregory P Swanson, Steven Stone,[...]. J Clin Oncol 2013
258
100

Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
D R Shepard, R Dreicer, J Garcia, P Elson, C Magi-Galluzzi, D Raghavan, A J Stephenson, E A Klein. J Urol 2009
33
100

Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
Scott E Eggener, Peter T Scardino, Patrick C Walsh, Misop Han, Alan W Partin, Bruce J Trock, Zhaoyong Feng, David P Wood, James A Eastham, Ofer Yossepowitch,[...]. J Urol 2011
457
100

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial.
G Aus, P-A Abrahamsson, G Ahlgren, J Hugosson, S Lundberg, M Schain, S Schelin, K Pedersen. BJU Int 2002
154
100

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
100

Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Jeffrey J Tosoian, Meera R Chappidi, Jay T Bishoff, Stephen J Freedland, Julia Reid, Michael Brawer, Steven Stone, Thorsten Schlomm, Ashley E Ross. BJU Int 2017
38
100

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
S Kumar, M Shelley, C Harrison, B Coles, T J Wilt, M D Mason. Cochrane Database Syst Rev 2006
168
100

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
Phillip G Febbo, Jerome P Richie, Daniel J George, Massimo Loda, Judith Manola, Sridhar Shankar, Agnieska Szot Barnes, Clare Tempany, William Catalona, Philip W Kantoff,[...]. Clin Cancer Res 2005
146
100

Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury,[...]. N Engl J Med 2014
100

Natural history of early, localized prostate cancer.
Jan-Erik Johansson, Ove Andrén, Swen-Olof Andersson, Paul W Dickman, Lars Holmberg, Anders Magnuson, Hans-Olov Adami. JAMA 2004
469
100

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Nicholas D James, Matthew R Sydes, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Christopher C Parker, J Martin Russell, Gerhardt Attard,[...]. Lancet 2016
100



Neoadjuvant hormonal therapy: the Canadian experience.
F Labrie, L Cusan, J L Gomez, P Diamond, R Suburu, M Lemay, B Tetu, Y Fradet, A Bélanger, B Candas. Urology 1997
65
100

Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
Ryan K Berglund, Catherine M Tangen, Isaac J Powell, Bruce A Lowe, Gabriel P Haas, Peter R Carroll, Edith D Canby-Hagino, Ralph deVere White, George P Hemstreet, E David Crawford,[...]. Urology 2012
29
100

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Bernhard J C Eigl, Scott E Eggener, Jenny Baybik, Susan Ettinger, Kim N Chi, Colleen Nelson, Zhou Wang, Martin E Gleave. Clin Cancer Res 2005
46
100

Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
David S Yee, William T Lowrance, James A Eastham, Alexandra C Maschino, Angel M Cronin, Farhang Rabbani. BJU Int 2010
41
100

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
A V D'Amico, R Whittington, S B Malkowicz, D Schultz, K Blank, G A Broderick, J E Tomaszewski, A A Renshaw, I Kaplan, C J Beard,[...]. JAMA 1998
100

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Jennifer Cullen, Inger L Rosner, Timothy C Brand, Nan Zhang, Athanasios C Tsiatis, Joel Moncur, Amina Ali, Yongmei Chen, Dejan Knezevic, Tara Maddala,[...]. Eur Urol 2015
198
100

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
Vinayak Muralidhar, Ming-Hui Chen, Gally Reznor, Brian J Moran, Michelle H Braccioforte, Clair J Beard, Felix Y Feng, Karen E Hoffman, Toni K Choueiri, Neil E Martin,[...]. Int J Radiat Oncol Biol Phys 2015
32
100


Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.
A V D'Amico, R Whittington, S B Malkowicz, J Fondurulia, M H Chen, I Kaplan, C J Beard, J E Tomaszewski, A A Renshaw, A Wein,[...]. J Clin Oncol 1999
298
100

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
100

Neoadjuvant Enzalutamide Prior to Prostatectomy.
Bruce Montgomery, Maria S Tretiakova, Anthony M Joshua, Martin E Gleave, Neil Fleshner, Glenn J Bubley, Elahe A Mostaghel, Kim N Chi, Daniel W Lin, Martin Sanda,[...]. Clin Cancer Res 2017
55
100

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gwenaelle Gravis, Karim Fizazi, Florence Joly, Stéphane Oudard, Franck Priou, Benjamin Esterni, Igor Latorzeff, Remy Delva, Ivan Krakowski, Brigitte Laguerre,[...]. Lancet Oncol 2013
423
100

Abiraterone in metastatic prostate cancer without previous chemotherapy.
Charles J Ryan, Matthew R Smith, Johann S de Bono, Arturo Molina, Christopher J Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng,[...]. N Engl J Med 2013
100

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Elahe A Mostaghel, Stephanie T Page, Daniel W Lin, Ladan Fazli, Ilsa M Coleman, Lawrence D True, Beatrice Knudsen, David L Hess, Colleen C Nelson, Alvin M Matsumoto,[...]. Cancer Res 2007
388
100

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).
Christopher Sweeney, Mari Nakabayashi, Meredith Regan, Wanling Xie, Julia Hayes, Nancy Keating, Suhui Li, Tomas Philipson, Marc Buyse, Susan Halabi,[...]. J Natl Cancer Inst 2015
46
100

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
Robert Dreicer, Cristina Magi-Galluzzi, Ming Zhou, Jason Rothaermel, Alwyn Reuther, James Ulchaker, Craig Zippe, Amr Fergany, Eric A Klein. Urology 2004
119
100

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.
Adam G Sowalsky, Huihui Ye, Manoj Bhasin, Eliezer M Van Allen, Massimo Loda, Rosina T Lis, Laleh Montaser-Kouhsari, Carla Calagua, Fen Ma, Joshua W Russo,[...]. Cancer Res 2018
39
100

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
Karim Fizazi, Howard I Scher, Kurt Miller, Ethan Basch, Cora N Sternberg, David Cella, David Forer, Mohammad Hirmand, Johann S de Bono. Lancet Oncol 2014
142
100

Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
Fausto Petrelli, Andrea Coinu, Mary Cabiddu, Mara Ghilardi, Ivano Vavassori, Sandro Barni. Eur Urol 2014
141
100

Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Ofer Yossepowitch, Scott E Eggener, Fernando J Bianco, Brett S Carver, Angel Serio, Peter T Scardino, James A Eastham. J Urol 2007
161
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.